PROQR THERAPEUTICS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.99 USD | +6.99% |
|
-9.55% | +0.51% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leberâs congenital amaurosis (LCA).
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.99
USD
Average target price
4.1
USD
Spread / Average Target
+106.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.51% | 162M | |
| -3.10% | 102B | |
| +2.11% | 96.37B | |
| -1.80% | 21.37B | |
| -17.75% | 20.92B | |
| -6.91% | 18.64B | |
| -42.00% | 16.4B | |
| -28.19% | 13.53B | |
| +0.18% | 13.28B | |
| +19.90% | 10.85B |
- Stock Market
- Equities
- PRQR Stock
- News ProQR Therapeutics N.V.
- ProQR Therapeutics N : Stifel Starts ProQR Therapeutics at Buy with $20 Price Target
